for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natco Pharma Ltd.

NATP.NS

Latest Trade

662.65INR

Change

17.95(+2.78%)

Volume

159,092

Today's Range

640.05

 - 

674.40

52 Week Range

480.00

 - 

738.10

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
644.70
Open
640.05
Volume
159,092
3M AVG Volume
4.52
Today's High
674.40
Today's Low
640.05
52 Week High
738.10
52 Week Low
480.00
Shares Out (MIL)
182.07
Market Cap (MIL)
117,379.20
Forward P/E
--
Dividend (Yield %)
0.99

Next Event

Dividend For NATP.NS - 3.5000 INR

Latest Developments

More

India's Natco Pharma Dec Quarter Consol Profit Falls

Natco Pharma Files ANDA For Tipiracil Hydrochloride Tablets For US Market

India's Natco Pharma Sept-Qtr Consol Net Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Natco Pharma Ltd.

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Contact Info

Natco House, Road No 2, Banjara Hills

+91.40.23547532

http://www.natcopharma.co.in/

Executive Leadership

V. C. Nannapaneni

Executive Chairman of the board, Managing Director

Rajeev Nannapaneni

Executive Vice Chairman of the Board, Chief Executive Officer

S. V. V. N. Appa Rao

Chief Financial Officer, Vice President - Finance and Accounts

Linga Rao

President - Technical Affairs, Director

P. S. R. K. Prasad

Executive Vice President - Corporate Engineering Services, Additional Wholetime Director

Key Stats

2.20 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

20.7K

2018

21.8K

2019

20.9K

2020(E)

20.2K
EPS (INR)

2017

27.750

2018

39.130

2019

34.870

2020(E)

28.644
Price To Earnings (TTM)
24.18
Price To Sales (TTM)
6.13
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
20.37
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Natco Pharma Dec Quarter Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES VERSUS 1.6 BILLION RUPEES YEAR AGO

MEDIA-Natco Pharma launches cut price versions of cancer drug ibrutinib in India - Economic Times

- Source link https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-versions-of-cancer-drug-ibrutinib-in-india/articleshow/72894811.cms

MEDIA-Delhi HC grants India's Natco Pharma interim relief in  BMS patents case - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BUZZ-India's Natco Pharma jumps as U.S. court affirms Teva's patents invalid

** Shares of India's Natco Pharma Ltd climb as much as 8.3 pct to 734 rupees, their biggest intraday pct gain since Oct. 5, 2017

BRIEF-Natco Pharma Files ANDA to U.S. FDA For Sofosbuvir Tablets

* SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FOR SOFOSBUVIR TABLETS, 400MG, WITH U.S. FDA

BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing

* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING

BRIEF-Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection

* NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA

BRIEF-India's Natco Pharma Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL NET PROFIT 2.18 BILLION RUPEES VERSUS PROFIT 1.95 BILLION RUPEES YEAR AGO

BRIEF-Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India

* SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA Source text for Eikon: Further company coverage:

BRIEF-Natco Pharma Approved Allocation Of 10 Mln Shares At 915 Rupees/Share Upon Closure Of QIP

* NATCO PHARMA - APPROVED ALLOCATION OF 10 MILLION SHARES AT ISSUE PRICE OF 915 RUPEES PER SHARE UPON CLOSURE OF QIP Source text: http://bit.ly/2zbT0ZA Further company coverage:

BRIEF-Natco Pharma Approves QIP Floor Price Of 937.63 Rupees/Shr

* SAYS APPROVED QIP FLOOR PRICE OF 937.63 RUPEES PER SHARE Source text: http://bit.ly/2AJA9El Further company coverage:

BRIEF-India's Natco Pharma Sept-qtr consol profit up about 28 pct

* Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year

BRIEF-Natco Pharma's marketing partner Mylan launches generic glatiramer acetate in U.S.

* Says marketing partner mylan launches generic glatiramer acetate in U.S. Market Source text - http://bit.ly/2xUtxo0 Further company coverage:

BUZZ-India's Natco Pharma rises; U.S. FDA approves generic for multiple sclerosis

** India's Natco Pharma Ltd surges 20 pct to 952.40 rupees to hit its upper circuit limit, the biggest intraday pct gain since July 29, 2013

BRIEF-Natco Pharma gets shareholders' nod for re-appointing V.C. Nannapaneni as chairman, MD

* Gets shareholders' nod for re-appointment of V.C. Nannapaneni as chairman, MD Source text - http://bit.ly/2wuXVkS Further company coverage:

MEDIA-India's Natco Pharma to expand API facility in Tamil Nadu - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

BRIEF-Natco Pharma gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

* Gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

BRIEF-Natco Pharma says co, Lupin get FDA nod for generic lanthanum carbonate chewable tablets

* Says Natco, Lupin get FDA nod for generic lanthanum carbonate chewable tablets

BRIEF-India's Natco Pharma June-qtr consol profit surges

* June quarter consol profit 940 million rupees versus profit of 477 million rupees last year

BRIEF-Natco Pharma gets final ANDA approval for azacitidine for injection

* Says Natco receives final approval for generic azacitidine for injection for USA market

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up